Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Immunome (IMNM) EPS (Weighted Average and Diluted) (2023 - 2025)

Immunome (IMNM) has disclosed EPS (Weighted Average and Diluted) for 3 consecutive years, with -$0.75 as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, EPS (Weighted Average and Diluted) rose 41.41% year-over-year to -$0.75, compared with a TTM value of -$2.43 through Dec 2025, up 53.0%, and an annual FY2025 reading of -$2.43, up 51.4% over the prior year.
  • EPS (Weighted Average and Diluted) was -$0.75 for Q4 2025 at Immunome, down from -$0.66 in the prior quarter.
  • Across five years, EPS (Weighted Average and Diluted) topped out at -$0.35 in Q3 2023 and bottomed at -$4.22 in Q4 2023.
  • Average EPS (Weighted Average and Diluted) over 3 years is -$1.08, with a median of -$0.63 recorded in 2024.
  • The sharpest move saw EPS (Weighted Average and Diluted) plummeted 617.14% in 2024, then surged 79.28% in 2025.
  • Year by year, EPS (Weighted Average and Diluted) stood at -$4.22 in 2023, then skyrocketed by 69.67% to -$1.28 in 2024, then surged by 41.41% to -$0.75 in 2025.
  • Business Quant data shows EPS (Weighted Average and Diluted) for IMNM at -$0.75 in Q4 2025, -$0.66 in Q3 2025, and -$0.5 in Q2 2025.